Stay tuned and follow the latest developments and news in Molecular Oncology.
Genekor’s scientific team, from the very first days of its establishment, has focused on the use and development of new technologies and the quality of services provided. In this way we have gained the trust of the medical community and patients, making us one of the leading laboratories in Europe.
Having long developed a complete portfolio of molecular services in oncology and knowing that there is a need for personalised treatment in other disciplines, we decided to expand into cardiology and neurology by adding three new families of tests to our portfolio – CordisDX®, CerebrumDX® and MyTheragene®.
Our development plan was not interrupted by covid-19, on the contrary, it helped us to create an even stronger and more effective team.
